氨甲环酸治疗产后出血的成本效果分析
本研究采用决策分析模型,比较产后出血治疗中使用氨甲环酸(1 g 静脉注射)与安慰剂的结局和成本,并比较早期给药(诊断后 3 小时内)与常规使用。结果显示早期给药可预防更多孕产妇死亡、剖腹术和再手术,增加质量调整生命年并节省成本,在绝大多数模型分析中为优势策略。
要点
- 氨甲环酸治疗产后出血在理论队列 10 万例中可预防 11 例孕产妇死亡、6 例阴道分娩后剖腹术和 112 例剖宫产后再手术。
- 早期给药(诊断后 3 小时内)可预防 16 例出血所致孕产妇死亡、9 例剖腹术和 155 例再手术。
- 敏感性分析显示氨甲环酸在孕产妇出血死亡概率 >0.00002 时均为优势策略,蒙特卡洛分析中早期给药在 99.8% 的模型中为优势策略。
核心结论
- 早期给予氨甲环酸是降低美国产后出血所致孕产妇发病率和死亡率的成本效果策略。
研究设计与样本
- 决策分析模型,比较静脉注射氨甲环酸 1 g 与匹配安慰剂,并比较早期给药(诊断后 3 小时内)与常规使用;概率、效用和成本来自文献,质量调整生命年按 3% 贴现率计算,支付意愿阈值为每质量调整生命年 100000 美元。
主要发现
- 敏感性分析显示,在孕产妇出血死亡概率 >0.00002 时氨甲环酸均为优势策略;当给药成本变化时,若在 3 小时内给药,氨甲环酸在美国每次给药成本高达 267 美元时仍为优势策略。
- 蒙特卡洛概率敏感性分析中,早期给予氨甲环酸在 99.8% 的模型中仍为优势策略(同时降低成本和改善结局)。
关键数值与推荐
- 世界卫生组织(WHO)目前推荐氨甲环酸作为产后出血的一线治疗;在美国,氨甲环酸目前被视为产后出血的辅助治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postpartum hemorrhage is a leading cause of pregnancy-related morbidity and mortality. Recent data have demonstrated that tranexamic acid reduces death because of bleeding when used as a treatment for postpartum hemorrhage. The World Health Organization now recommends tranexamic acid as a first-line treatment for postpartum hemorrhage; however, data are not yet available on the frequency of use in the United States, where tranexamic acid is currently recognized as an adjunct treatment for postpartum hemorrhage. OBJECTIVE: We aimed to strengthen the current evidence that tranexamic acid should be recognized as a first-line treatment for postpartum hemorrhage, even in high-resource countries. Furthermore, we aimed to determine whether early administration of tranexamic acid (within 3 hours of diagnosis) is a cost-effective strategy for reducing maternal morbidity and mortality from postpartum hemorrhage in the United States. STUDY DESIGN: A decision-analytical model was designed to compare the outcomes and costs of the administration of tranexamic acid in the treatment of postpartum hemorrhage. Moreover, this model was used to compare outcomes for early administration with those of routine use. The interventions compared were 1 g of intravenous tranexamic acid or matching placebo. The risks analyzed in the model were death because of hemorrhage and laparotomy to control bleeding. Probabilities, utilities, and costs were derived from literature. Quality-adjusted life-years were calculated using a discounted life expectancy rate of 3%. Cost-effectiveness was determined on the basis of a willingness-to-pay threshold of $100,000 per quality-adjusted life year. RESULTS: The administration of tranexamic acid to a theoretical cohort of 100,000 women would prevent 11 maternal deaths, 6 postpartum laparotomies after vaginal delivery, and 112 reoperations after cesarean delivery. This would lead to an increase in 329 quality-adjusted life years and a total cost savings of $15.39 million. Furthermore, if tranexamic acid were administered early (within 3 hours of postpartum hemorrhage diagnosis) to the same theoretical cohort, 16 maternal deaths owing to hemorrhage, 9 laparotomies, and 155 reoperations would be prevented. This amounts to an increase in 438 quality-adjusted life years and an annual cost savings of $23.15 million. A sensitivity analysis showed that the administration of tranexamic acid was the dominant strategy at all probabilities of maternal death owing to hemorrhage >0.00002. When the cost of tranexamic acid was varied, the administration of tranexamic acid remained dominant up to a cost of $267 per administration in the United States if given within the first 3 hours. Furthermore, in a Monte Carlo probabilistic sensitivity analysis, the early administration of tranexamic acid remained the dominant strategy (both lowered costs and improved outcomes) in 99.8% of models. CONCLUSION: Early administration of tranexamic acid was a cost-effective strategy for reducing maternal morbidity and mortality owing to postpartum hemorrhage in the United States.
引用
- Howard DC, Jones AE, Skeith A, et al. Tranexamic acid for the treatment of postpartum hemorrhage: a cost-effectiveness analysis. Am J Obstet Gynecol MFM. 2022. PMID: 35124299. doi:10.1016/j.ajogmf.2022.100588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。